160 related articles for article (PubMed ID: 31434215)
1. Lipolytic Effects of 3-Iodothyronamine (T1AM) and a Novel Thyronamine-Like Analog SG-2 through the AMPK Pathway.
Rogowski M; Bellusci L; Sabatini M; Rapposelli S; Rahman SM; Chiellini G; Assadi-Porter FM
Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31434215
[TBL] [Abstract][Full Text] [Related]
2. The metabolic suppressor 3-iodothyronamine enhances lipolysis in 3T3-L1 adipocytes via activation of the adenosine monophosphate-activated protein kinase/forkhead box O1 signaling pathway.
Kim M; Park K; Choi I
J Physiol Pharmacol; 2020 Jun; 71(3):. PubMed ID: 33077693
[TBL] [Abstract][Full Text] [Related]
3. Endogenous 3-Iodothyronamine (T1AM) and Synthetic Thyronamine-like Analog SG-2 Act as Novel Pleiotropic Neuroprotective Agents Through the Modulation of SIRT6.
Bellusci L; Runfola M; Carnicelli V; Sestito S; Fulceri F; Santucci F; Lenzi P; Fornai F; Rapposelli S; Origlia N; Zucchi R; Chiellini G
Molecules; 2020 Feb; 25(5):. PubMed ID: 32110992
[TBL] [Abstract][Full Text] [Related]
4. Uptake of 3-iodothyronamine hormone analogs inhibits the growth and viability of cancer cells.
Rogowski M; Gollahon L; Chellini G; Assadi-Porter FM
FEBS Open Bio; 2017 Apr; 7(4):587-601. PubMed ID: 28396842
[TBL] [Abstract][Full Text] [Related]
5. Modulation of gene expression by 3-iodothyronamine: genetic evidence for a lipolytic pattern.
Mariotti V; Melissari E; Iofrida C; Righi M; Di Russo M; Donzelli R; Saba A; Frascarelli S; Chiellini G; Zucchi R; Pellegrini S
PLoS One; 2014; 9(11):e106923. PubMed ID: 25379707
[TBL] [Abstract][Full Text] [Related]
6. 3-Iodothyronamine and 3,5,3'-triiodo-L-thyronine reduce SIRT1 protein expression in the HepG2 cell line.
Sacripanti G; Lorenzini L; Bandini L; Frascarelli S; Zucchi R; Ghelardoni S
Horm Mol Biol Clin Investig; 2020 Mar; 41(1):. PubMed ID: 32114521
[TBL] [Abstract][Full Text] [Related]
7. 3-Iodothyronamine Decreases Expression of Genes Involved in Iodide Metabolism in Mouse Thyroids and Inhibits Iodide Uptake in PCCL3 Thyrocytes.
Schanze N; Jacobi SF; Rijntjes E; Mergler S; Del Olmo M; Hoefig CS; Khajavi N; Lehmphul I; Biebermann H; Mittag J; Köhrle J
Thyroid; 2017 Jan; 27(1):11-22. PubMed ID: 27788620
[TBL] [Abstract][Full Text] [Related]
8. 3-Iodothyronamine reduces insulin secretion in vitro via a mitochondrial mechanism.
Lehmphul I; Hoefig CS; Köhrle J
Mol Cell Endocrinol; 2018 Jan; 460():219-228. PubMed ID: 28754352
[TBL] [Abstract][Full Text] [Related]
9. New Insights into the Potential Roles of 3-Iodothyronamine (T1AM) and Newly Developed Thyronamine-Like TAAR1 Agonists in Neuroprotection.
Bellusci L; Laurino A; Sabatini M; Sestito S; Lenzi P; Raimondi L; Rapposelli S; Biagioni F; Fornai F; Salvetti A; Rossi L; Zucchi R; Chiellini G
Front Pharmacol; 2017; 8():905. PubMed ID: 29311919
[TBL] [Abstract][Full Text] [Related]
10. Uptake and metabolic effects of 3-iodothyronamine in hepatocytes.
Ghelardoni S; Chiellini G; Frascarelli S; Saba A; Zucchi R
J Endocrinol; 2014 Apr; 221(1):101-10. PubMed ID: 24627446
[TBL] [Abstract][Full Text] [Related]
11. 3-Iodothyronamine: a novel hormone controlling the balance between glucose and lipid utilisation.
Braulke LJ; Klingenspor M; DeBarber A; Tobias SC; Grandy DK; Scanlan TS; Heldmaier G
J Comp Physiol B; 2008 Feb; 178(2):167-77. PubMed ID: 17912534
[TBL] [Abstract][Full Text] [Related]
12. Metabolic Reprogramming by 3-Iodothyronamine (T1AM): A New Perspective to Reverse Obesity through Co-Regulation of Sirtuin 4 and 6 Expression.
Assadi-Porter FM; Reiland H; Sabatini M; Lorenzini L; Carnicelli V; Rogowski M; Selen Alpergin ES; Tonelli M; Ghelardoni S; Saba A; Zucchi R; Chiellini G
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29786646
[TBL] [Abstract][Full Text] [Related]
13. Metabolic profiling reveals reprogramming of lipid metabolic pathways in treatment of polycystic ovary syndrome with 3-iodothyronamine.
Selen Alpergin ES; Bolandnazar Z; Sabatini M; Rogowski M; Chiellini G; Zucchi R; Assadi-Porter FM
Physiol Rep; 2017 Jan; 5(1):. PubMed ID: 28082426
[TBL] [Abstract][Full Text] [Related]
14. 3-iodothyronamine differentially modulates α-2A-adrenergic receptor-mediated signaling.
Dinter J; Mühlhaus J; Jacobi SF; Wienchol CL; Cöster M; Meister J; Hoefig CS; Müller A; Köhrle J; Grüters A; Krude H; Mittag J; Schöneberg T; Kleinau G; Biebermann H
J Mol Endocrinol; 2015 Jun; 54(3):205-16. PubMed ID: 25878061
[TBL] [Abstract][Full Text] [Related]
15. Inverse agonistic action of 3-iodothyronamine at the human trace amine-associated receptor 5.
Dinter J; Mühlhaus J; Wienchol CL; Yi CX; Nürnberg D; Morin S; Grüters A; Köhrle J; Schöneberg T; Tschöp M; Krude H; Kleinau G; Biebermann H
PLoS One; 2015; 10(2):e0117774. PubMed ID: 25706283
[TBL] [Abstract][Full Text] [Related]
16. 3-Iodothyronamine Affects Thermogenic Substrates' Mobilization in Brown Adipocytes.
Gencarelli M; Laurino A; Landucci E; Buonvicino D; Mazzantini C; Chiellini G; Raimondi L
Biology (Basel); 2020 May; 9(5):. PubMed ID: 32375297
[TBL] [Abstract][Full Text] [Related]
17. Tissue distribution and cardiac metabolism of 3-iodothyronamine.
Saba A; Chiellini G; Frascarelli S; Marchini M; Ghelardoni S; Raffaelli A; Tonacchera M; Vitti P; Scanlan TS; Zucchi R
Endocrinology; 2010 Oct; 151(10):5063-73. PubMed ID: 20739399
[TBL] [Abstract][Full Text] [Related]
18. The impact of scopolamine pretreatment on 3-iodothyronamine (T1AM) effects on memory and pain in mice.
Laurino A; Lucenteforte E; De Siena G; Raimondi L
Horm Behav; 2017 Aug; 94():93-96. PubMed ID: 28711308
[TBL] [Abstract][Full Text] [Related]
19. Central Effects of 3-Iodothyronamine Reveal a Novel Role for Mitochondrial Monoamine Oxidases.
Laurino A; Landucci E; Raimondi L
Front Endocrinol (Lausanne); 2018; 9():290. PubMed ID: 29928258
[TBL] [Abstract][Full Text] [Related]
20. Vitamin D decreases adipocyte lipid storage and increases NAD-SIRT1 pathway in 3T3-L1 adipocytes.
Chang E; Kim Y
Nutrition; 2016 Jun; 32(6):702-8. PubMed ID: 26899162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
